Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.
Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.
复制标题
DOI：
10.4155/bio.12.325
复制
发表时间：
2013-02
期刊：
影响因子：
1.8
通讯作者：
Henderson PT
中科院分区：
文献类型：
--
作者：
Cimino GD;Pan CX;Henderson PT
癌症化疗领域正在发生个性化医疗革命。生物标志物越来越能够区分个体肿瘤的基因型或表型特征，并且与治疗方案的选择相关。本综述涵盖了对靶向细胞毒性肺癌和膀胱癌治疗产生反应的生物标志物的分子基础，重点是铂类化疗。铂衍生物是一类常用于对抗实体瘤的药物，通过与 DNA 共价连接来杀死细胞。患者组织中的铂-DNA 加合物水平与反应和生存相关。加合物检测的灵敏度和精确度已提高到能够在开始全剂量治疗之前用于诊断应用的亚治疗剂量，称为诊断微剂量。详细介绍了这种独特的表型标记在肺癌和膀胱癌应用中的临床状况，并讨论了未来的应用。
The personalized medicine revolution is occurring for cancer chemotherapy. Biomarkers are increasingly capable of distinguishing genotypic or phenotypic traits of individual tumors, and are being linked to the selection of treatment protocols. This review covers the molecular basis for biomarkers of response to targeted and cytotoxic lung and bladder cancer treatment with an emphasis on platinum-based chemotherapy. Platinum derivatives are a class of drugs commonly employed against solid tumors that kill cells by covalent attachment to DNA. Platinum–DNA adduct levels in patient tissues have been correlated to response and survival. The sensitivity and precision of adduct detection has increased to the point of enabling subtherapeutic dosing for diagnostics applications, termed diagnostic microdosing, prior to the initiation of full-dose therapy. The clinical status of this unique phenotypic marker for lung and bladder cancer applications is detailed along with discussion of future applications.
登录
查看更多内容
影响因子：
14.9
作者：
BLOMMAERT, FA;SARIS, CP
通讯作者：
SARIS, CP
影响因子：
50.5
作者：
Bellmunt, J.;Paz-Ares, L.;Baselga, J.
通讯作者：
Baselga, J.
影响因子：
45.3
作者：
Cappuzzo, F;Gregorc, V;Crinò, L
通讯作者：
Crinò, L
影响因子：
50.5
作者：
Comella, P.;Filippelli, G.;Masullo, P.
通讯作者：
Masullo, P.
影响因子：
4.1
作者：
Baskerville-Abraham, Irene M.;Boysen, Gunnar;Swenberg, James A.
通讯作者：
Swenberg, James A.